|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273 e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gomaa AI, Khan SA, Toledano MB, Waked I
and Taylor-Robinson SD: Hepatocellular carcinoma: Epidemiology,
risk factors and pathogenesis. World J Gastroenterol. 14:4300–4308.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rapisarda V, Loreto C, Malaguarnera M,
Ardiri A, Proiti M, Rigano G, Frazzetto E, Ruggeri MI, Malaguarnera
G, Bertino N, et al: Hepatocellular carcinoma and the risk of
occupational exposure. World J Hepatol. 8:573–590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Felekkis K, Touvana E, Stefanou CH and
Deltas C: microRNAs: A newly described class of encoded molecules
that play a role in health and disease. Hippokratia. 14:236–240.
2010.PubMed/NCBI
|
|
5
|
Hung CH, Chiu YC, Chen CH and Hu TH:
MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression,
and therapeutic target. Biomed Res Int. 2014:4864072014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ding Y, Yan JL, Fang AN, Zhou WF and Huang
L: Circulating miRNAs as novel diagnostic biomarkers in
hepatocellular carcinoma detection: A meta-analysis based on 24
articles. Oncotarget. 8:66402–66413. 2017.PubMed/NCBI
|
|
7
|
Loosen SH, Schueller F, Trautwein C, Roy S
and Roderburg C: Role of circulating microRNAs in liver diseases.
World J Hepatol. 9:586–594. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chickooree D, Zhu K, Ram V, Wu HJ, He ZJ
and Zhang S: A preliminary microarray assay of the miRNA expression
signatures in buccal mucosa of oral submucous fibrosis patients. J
Oral Pathol Med. 45:691–697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lai NS, Yu HC, Tung CH, Huang KY, Huang HB
and Lu MC: The role of aberrant expression of T cell miRNAs
affected by TNF-α in the immunopathogenesis of rheumatoid
arthritis. Arthritis Res Ther. 19:2612017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwaya T, Fukagawa T, Suzuki Y, Takahashi
Y, Sawada G, Ishibashi M, Kurashige J, Sudo T, Tanaka F, Shibata K,
et al: Contrasting expression patterns of histone mRNA and microRNA
760 in patients with gastric cancer. Clin Cancer Res. 19:6438–6449.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu SH, Wang CH, Huang ZJ, Liu F, Xu CW, Li
XL and Chen GQ: miR-760 mediates chemoresistance through inhibition
of epithelial mesenchymal transition in breast cancer cells. Eur
Rev Med Pharmacol Sci. 20:5002–5008. 2016.PubMed/NCBI
|
|
12
|
Lv J, Fu Z, Shi M, Xia K, Ji C, Xu P, Lv
M, Pan B, Dai L and Xie H: Systematic analysis of gene expression
pattern in has-miR-760 overexpressed resistance of the MCF-7 human
breast cancer cell to doxorubicin. Biomed Pharmacother. 69:162–169.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lv J, Xia K and Xu P: miRNA expression
patterns in chemoresistant breast cancer tissues. Biomedi
Pharmacother. 68:935–942. 2014. View Article : Google Scholar
|
|
14
|
Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang
L, Huang D, Tan C, Sheng W and Du X: Plasma miR-601 and miR-760 are
novel biomarkers for the early detection of colorectal cancer. PLoS
One. 7:e443982012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liao Y, Deng Y, Liu J, Ye Z, You Z, Yao S
and He S: MiR-760 overexpression promotes proliferation in ovarian
cancer by downregulation of PHLPP2 expression. Gynecol Oncol.
143:655–663. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han ML, Wang F, Gu YT, Pei XH, Ge X, Guo
GC, Li L, Duan X, Zhu MZ and Wang YM: MicroR-760 suppresses cancer
stem cell subpopulation and breast cancer cell proliferation and
metastasis: By down-regulating NANOG. Biomed Pharmacother.
80:304–310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee YH, Kim SY and Bae YS: Upregulation of
miR-760 and miR-186 is associated with replicative senescence in
human lung fibroblast cells. Mol Cells. 620–627. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Elshafei A, Shaker O, Abd El-Motaal O and
Salman T: The expression profiling of serum miR-92a, miR-375 and
miR-760 in colorectal cancer: An Egyptian Study. Tumour Biol.
39:10104283177057652017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng Q, Chen C, Guan H, Kang W and Yu C:
Prognostic role of microRNAs in human gastrointestinal cancer: A
systematic review and meta-analysis. Oncotarget. 8:46611–46623.
2017.PubMed/NCBI
|
|
20
|
Lánczky A, Nagy Á, Bottai G, Munkácsy G,
Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to
validate survival-associated miRNAs utilizing expression data from
2178 breast cancer patients. 160:439–446. 2016.
|
|
21
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ananthakrishnan A, Gogineni V and Saeian
K: Epidemiology of primary and secondary liver cancers. Semin
Intervent Radiol. 23:47–63. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee JG, Kang CM, Park JS, Kim KS, Yoon DS,
Choi JS, Lee WJ and Kim BR: The actual five-year survival rate of
hepatocellular carcinoma patients after curative resection. Yonsei
Med J. 47:105–112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Waghray A, Murali AR and Menon KN:
Hepatocellular carcinoma: From diagnosis to treatment. World J
Hepatol. 7:1020–1029. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wan DW, Tzimas D, Smith JA, Kim S, Araujo
J, David R, Lobach I and Sarpel U: Risk factors for early-onset and
late-onset hepatocellular carcinoma in Asian immigrants with
hepatitis B in the United States. Am J Gastroenterol.
106:1994–2000. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mehra M and Chauhan R: Long noncoding RNAs
as a key player in hepatocellular carcinoma. Biomark Cancer.
9:1179299X177373012017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gramantieri L, Fornari F, Callegari E,
Sabbioni S, Lanza G, Croce CM, Bolondi L and Negrini M: MicroRNA
involvement in hepatocellular carcinoma. J Cell Mol Med.
12:2189–2204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang CS, Yu W, Cui H, Wang YJ, Zhang L,
Han F and Huang T: Increased expression of miR-21 predicts poor
prognosis in patients with hepatocellular carcinoma. Int J Clin Exp
Pathol. 8:7234–7238. 2015.PubMed/NCBI
|
|
29
|
Liu AM, Yao TJ, Wang W, Wong KF, Lee NP,
Fan ST, Poon RT, Gao C and Luk JM: Circulating miR-15b and miR-130b
in serum as potential markers for detecting hepatocellular
carcinoma: A retrospective cohort study. BMJ Open. 2:e0008252012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qi P, Cheng SQ, Wang H, Li N, Chen YF and
Gao CF: Serum microRNAs as biomarkers for hepatocellular carcinoma
in Chinese patients with chronic hepatitis B virus infection. PLoS
One. 6:e284862011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan C, Zhang W, Shi X, Zheng J, Jin X and
Huo J: MiR-760 suppresses non-small cell lung cancer proliferation
and metastasis by targeting ROS1. Environ Sci Pollut Res Int.
25:18385–18391. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao L, Liu Y, Wang D, Huang L, Li F, Liu
J, Zhang C, Shen Z, Gao Q, Yuan W and Zhang Y: MiR-760 suppresses
human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1
signaling. J Exp Clin Cancer Res. 37:832018. View Article : Google Scholar : PubMed/NCBI
|
